Bachem has announced that its Sisslerfeld peptide production site is expected to begin commercial manufacturing in the year 2030. The company provided this timeline for when the facility will transition to full-scale commercial operations. The Sisslerfeld site is dedicated to peptide production,…
Bachem expects the Sisslerfeld peptide production site to begin commercial manufacturing in the year 2030. This timeline was announced by the company, outlining when the facility is anticipated to reach full operational status. The Sisslerfeld site is dedicated to peptide production, an area of focus for Bachem's manufacturing network. The company has set this target without providing additional information about the current phase of development or specific investments associated with the site.
The facility is designed specifically for the production of peptides, which are short chains of amino acids used in various pharmaceutical applications. Bachem intends to transition the site to commercial production, meaning it will produce peptides for sale to customers. The 2030 target provides a long-range schedule for this transition. Peptide manufacturing requires specialized equipment and processes, and the Sisslerfeld site is being developed to meet these needs. Bachem's focus on peptide production is central to its role in the pharmaceutical supply chain.
Setting a specific year for commercial production indicates Bachem's forward planning for expanding its manufacturing capacity. The Sisslerfeld site will join the company's existing production facilities once it becomes operational. The announcement does not include details on the current construction stage or investment amounts, focusing solely on the anticipated operational start date. This timeline gives visibility into Bachem's long-term strategy for peptide manufacturing.
The 2030 target provides clarity for Bachem's stakeholders regarding the timeline for new commercial capacity. As the company develops the Sisslerfeld site, it will work toward meeting this deadline. No further milestones or progress updates have been shared at this time. Bachem will continue to update the market as the site progresses toward the 2030 commercial production start. The company has not disclosed any interim targets or expected production volumes for the site.
Vendors referenced: Peptides For Sale.
Related reading: Bachem Invests Over CHF 500 Million in New Peptide Facility in Sisslerfeld, Samsung Biologics to Acquire PolyPeptide for $1.8 Billion, Expanding into GLP-1 Market, Samsung Biologics Expands Peptide Capacity to Lead Obesity Drug CDMO, Samsung Biologics Offers $1.8 Billion for Swiss Peptide CDMO PolyPeptide.